Collaborating with patients: learning from psoriasis and other diseases
|
|
- Dylan Day
- 6 years ago
- Views:
Transcription
1 Collaborating with patients: learning from psoriasis and other diseases Marilyn Metcalf, PhD Sr. Dir., Benefit Risk Evaluation Chief Medical Office EveryLife Foundation for Rare Diseases September 15, 2015 Washington, DC On behalf of Kay Warner, Manager, Focus on the Patient Fabrizia Bignami Head, Patient Engagement and Public Affairs, Rare Diseases Unit Namrata Taak, Global Pipeline Comms Dir. Sue Vallow, Head, Patient Focused Outcomes
2 From our Chief Medical Office We have an obligation to learn from physicians and patients and to make sure we provide accurate and complete information to them through appropriate channels; but we must do this in a careful, correct, nonpromotional manner. - Scientific Engagement Global Standards 2
3 Listening to and learning from patients and carers 11 years ago GSK established the program Focus on the Patient Brings patients to GSK sites Main component is awareness seminars Hear directly from patients, caregivers and advocates Raise general awareness of the multidimensional aspects of a disease clinical course, effects on daily life, personal experiences Provide summary of GSK efforts to meet patient needs holds a mirror up to us on where we re hitting the mark and where we re falling short 3
4 Patient and employee feedback The timing was perfect since we are working on one of our projects for Scleroderma. Having a chance to meet with the patients ahead of this was an excellent experience for me. John, Discovery Medicine, BioPharm 4
5 Recent and future Focus on the Patient topics 2013: Neglected tropical diseases, COPD, type 2 diabetes, gene therapy, HIV, chronic hand ezcema, Duchenne muscular dystrophy 2014: Cancer care in Africa and our alliance with NGOs in the region, severe aplastic anemia, motor neurone disease (MND) including amyotrophic lateral sclerosis (ALS), eosinophilic granulomatosis with polyangiitis (EGPA), pediatric ITP 2015: Breast cancer, zoster/vaccines, Parkinson s Disease, severe eosinophilic asthma, respiratory, metachromatic leukodystrophy (MLD) 5
6 23 July 2014, BERLIN Case Study: Psoriasis December 2012 to January 2013 Focus on the Patient partnership with Biopharm Discovery Medicine & Commercial Strategy Held individual interviews at GSK, Learned patient insights and perspective of their disease, its impact on them and carers Influenced study endpoints for clinical trials, target patient population, device design changes Sent letter to patients thanking them for participation and outlining key collective findings More teams seeking patient insight for a variety of reasons 6
7 Learning to meet challenges Identifying patients: good networks are key Written language in legal contracts: more reader friendly Understanding internal polices and the external Code of Practice we can and should talk to patients Early phase drugs are less likely to succeed, so earlier involvement will include work on drugs that have less chance of success BUT learning isn t wasted we carry it forward 7
8 Votrient in advanced soft tissue sarcoma trial design Patient voices improved the Phase II first line maintenance study of Votrient in advanced soft tissue sarcoma The drug development team was better able to select disease symptoms measured as a trial outcome, along with the time-frame in which data was collected. The early discussion with patients improved the collection process of patient reported symptoms Streamlined design Trial less burdensome but more relevant to patients 8
9 Case Study: Duchenne Muscular Dystrophy (DMD) Patient Group Meetings: Sharing GSK updates on the drisapersen clinical programme when public keeping the patient community up to date with our progress. Patient Case Studies: Experience of investigators and patients highlight the key effects of a treatment in an accessible format. Case reports prepared by drisapersen investigators showed the human impact of the disease and treatment, which were informative to GSK in drug development and could inform payers to help secure reimbursement. 9
10 From Case Reports, EUPATI WORKSHOP MEANINGFUL PATIENT INVOLVEMENT IN INDUSTRY-LED MEDICINES R&D 23 July 2014, BERLIN 10
11 20 th September The Day the Ph III drisapersen study results went public... Shock to the community... Complete shock We can't see him on a wheel chair May the good Lord guide you and your entire company in the right path Please restart the program and save the life of the younger kids Falling Trying to come to grips with the apart enormity of what has transpired over the last week 11
12 Sequence of Events Rapid Patient Community Engagement Day Zero: Press Release goes Public Day Zero: E-Communication to Patient Groups Heads & Multiple 1:1 Phone calls to provide support Day One: Start of multiple enquiries from patients and parents +++ each individually and personally answered Day One: Teleconference with Patient Groups to discuss results, how best to support them and planned next steps Day 10 : External Q & A Provided to Patient Groups to support them with enquiries from their members this is then posted onto multiple PAG websites Day 11: WMS Congress Medical Booth to provide a face to face extension of our medical information service Day 17: Global Webinar organised for the patient community to help answer any questions recording and also slides provided for PAG websites November : GSK invited to provide update at Patient Conference (Action Duchenne) 12
13 The Community Advisory Board (CAB) of patients and caregivers was loud and clear about what was important to them, to us prioritize slowing or halting disease progression, recommend no or minimal exposure to placebo, encourage trials that include all individuals (young, adult, walking and non-ambulatory), use regulatory tools such as Accelerated Approval a loud urgent voice for unmet needs. GSK was privileged to be one of many contributors to the June 2014 community led guidance that preceded FDA s post 13
14 Drisapersen under review for treatment of some Duchenne patients 14
15 Case Study: ADA SCID Gene Therapy US and EU patient groups engaged in a dialogue to enhance our understanding of the patient s journey and that of their family from diagnosis to care and treatment primary immune deficiencies (PID) adenosine deaminase severe combined immunodeficiency syndrome (ADA SCID). Also identified needs and expectations of this community. 15
16 An application is under consideration 16
17 Our gratitude to our patients and their families, and to our other collaborators Patrick Vallance, President of Pharmaceuticals R&D at GSK, said: I am very pleased that we are now at a stage to file for approval of this gene therapy for ADA-SCID a devastating rare disease which drastically limits and shortens patients lives. Development of this therapy would not have been possible without the immense support of the ADA-SCID patients families and the work of so many pioneering scientists who have worked in this cutting edge area of medicine for decades. We are privileged to take forward this submission. Press Release 05 May 2015: GSK, Fondazione Telethon and Ospedale San Raffaele announce EU regulatory submission for gene therapy to treat rare disease ADA-SCID 17
18 Case Study: ADA SCID Gene Therapy Development of a post marketing evidence generation strategy. If gene therapy (GT) for ADA SCID is approved, an ADA SCID gene therapy registry will be required and will be: The core of the ADA SCID GT Risk Management Plan, The evidence generation tool that will track safety signals and will confirm and support the value of the product over the long term. Unique challenges compared to any existing drug registry. 18
19 Growing collaborations, more patient leadership EUPATI Patient-led five year project under the Innovative Medicines Initiative (IMI) launched in February 2012 GSK provides in-kind contribution Helps patients prepare for participation in scientific, ethical and regulatory committees that can accelerate and improve clinical trials, drug development and access strategies. FasterCures Center of the Milken Institute, an action tank with the goal to save lives by speeding up and improving the medical research system September 2014 Benefit-Risk Boot Camp, led by and designed for patient organization staff members, patient advocates, policy makers, and other stakeholders to hear directly from experts about enhancing patient-centered decision-making about medical products GSK participated in Boot Camp and continues on FC s Benefit-Risk Advisory Council 19
20 Implementing through internal efforts, e.g., Patient Engagement Plans Contents Patient Engagement Plan for [Disease] Programme Introduction Understanding the [Disease] patient journey Defining the [Disease] patient care-path General [Disease] Patient Engagement Communication Plan Summary of Activities Immediate Implementation Appendix A: [Disease] Patient Advocacy Groups & Foundations Appendix B: Communication Structure to Support Programme 20
21 What next? Continue participating in patient-led and patient co-led efforts Continue to point drug development teams to patient engagement resources Look for new opportunities moving forward 21
22 THANK YOU 22
THE PHARMACEUTICAL MARKETING SOCIETY
THE PHARMACEUTICAL MARKETING SOCIETY Welcome Agenda: About PM Society The PM Society The PM Society was established over 40 years ago as a not for profit organisation to serve the needs of the pharmaceutical
More informationEuropean Patients Academy on Therapeutic Innovation
European Patients Academy on Therapeutic Innovation http://www.patientsacademy.eu info@patientsacademy.eu The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under
More informationPatient First Drug Development:
Patient First Drug Development: Exploring the patient perspective M-CERSI Bethesda March 9, 2015 Tom Murphy, PatientsLikeMe member & PALS Advocate Sally Okun, VP Advocacy, Policy & Patient Safety mir.
More informationEUPATI PROJECT: EXECUTIVE SUMMARY
EUPATI PROJECT: EXECUTIVE SUMMARY Table of Contents 1 Overall objectives of EUPATI... 1 2 Results and successes of the EUPATI Project... 1 3 EUPATI s Future... 4 4 About this document... 5 1 Overall objectives
More informationNovartis Oncology Professional Medical Education and Patient Advocacy Grants
Novartis Oncology Professional Medical Education and Patient Advocacy Grants For more information, please visit the Novartis Grants Central Station website at www.ngcs.novartis.com. PROFESSIONAL MEDICAL
More informationPatient information and how patient advocacy can strengthen education and best practice
European CME Forum 2010 Patient information and how patient advocacy can strengthen education and best practice 1 Jan Geissler Founder and chair, Leukämie-Online e.v. Co-founder, CML Advocates Network
More informationConfronting the Challenges of Rare Disease:
Confronting the Challenges of Rare Disease: SOLUTIONS ACROSS THE ENTIRE PRODUCT LIFE CYCLE The Orphan Drug Act of 1983 brought increased awareness to the need for new treatments for rare disease patients
More informationEXPANDING THE SCIENCE OF PATIENT INPUT: Pain Points and Potential
EXPANDING THE SCIENCE OF PATIENT INPUT: Pain Points and Potential Table of Contents 2 INTRODUCTION 4 KEY TAKEAWAYS 6 SIGNS OF SUCCESS 14 SCIENCE OF PATIENT INPUT: THE NEED FOR A COMMON LANGUAGE 16 THE
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Centre for Health Technology Evaluation
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Health Technology Evaluation Increasing capacity within Technology Appraisals Consultation comments proforma Name Role Organisation E-Mail Address
More informationFebruary 27, Senate Committee on Armed Services House Committee on Armed Services. Washington, DC Washington, DC 20515
The Honorable John McCain The Honorable Mac Thornberry Chairman Chairman Senate Committee on Armed Services House Committee on Armed Services Russell Senate Building, Room 228 2216 Rayburn House Office
More informationIPOPI Indonesian PID Clinical Care Meeting and National PID Patients Meeting Jakarta, Indonesia 6 th and 7 th of May Report
IPOPI Indonesian PID Clinical Care Meeting and National PID Patients Meeting Jakarta, Indonesia 6 th and 7 th of May 2017 Introduction Report The National Indonesian PID Clinical Care Meeting took place
More informationBuilding Smarter Patient Registries. A report from FasterCures Patients Count: The Science of Patient Input program
Building Smarter Patient Registries A report from FasterCures Patients Count: The Science of Patient Input program The collection of patient data, via tools like patient registries, allows for various
More informationSEEKING PATIENT PERSPECTIVES IN CLINICAL TRIAL DESIGN AMY FROMENT, GLOBAL FEASIBILITY OPERATIONS DIR THE PATIENT S VOICE 2017
SEEKING PATIENT PERSPECTIVES IN CLINICAL TRIAL DESIGN AMY FROMENT, GLOBAL FEASIBILITY OPERATIONS DIR THE PATIENT S VOICE 2017 IMPORTANT CONTEXT As a biopharmaceutical business, Amgen is a commercial entity.
More informationOn April 19, 2007, the National Working Group on
On April 19, 2007, the National Working Group on Evidence-Based Health Care (the Working Group) hosted a consumer forum on the central role patients should play in evidence-based health care (EBH). The
More informationTalking to Your Doctor About Hospice Care
Talking to Your Doctor About Hospice Care Death and dying subjects that were once taboo in our culture are becoming increasingly relevant as more Americans care for their aging parents and consider what
More information1. Introduction, purpose of this Standard Operating Procedure (SOP)
SOP-CTN-001- Clinical Trial Network - General Organisation and Principles European Society of Anaesthesiology Details Document Type Document name Ref # Version Effective from Review date Owner Prepared
More informationIntroduction Patient-Centered Outcomes Research Institute (PCORI)
2 Introduction The Patient-Centered Outcomes Research Institute (PCORI) is an independent, nonprofit health research organization authorized by the Patient Protection and Affordable Care Act of 2010. Its
More informationPatient Involvement at
Patient Involvement at Andrea Furia-Helms, MPH FDA Patient Representative Program Office of Health and Constituent Affairs Food and Drug Administration (FDA) White Oak Campus Silver Spring, Maryland FDA
More informationNEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use EMEA/267187/2005/ Rev. 1 London, 26 April 2006 NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE The CPMP/CHMP
More informationJOB DESCRIPTION. Clinical Scientist. Molecular Genetics, Genetics Centre. Molecular Genetics, Genetics Centre, Viapath, Guy s Hospital
JOB DESCRIPTION JOB TITLE: Clinical Scientist GRADE: Band 7 DEPARTMENT: LOCATION: RESPONSIBLE TO: Molecular Genetics, Genetics Centre Molecular Genetics, Genetics Centre, Viapath, Guy s Hospital Molecular
More information1. Introduction, purpose of this Standard Operating Procedure (SOP)
Details Document Type Document name Ref # Version Effective from Review date Owner Prepared by Reviewed by Approved by Superseded documents Relevant regulations/legislation/guidelines/reference Standard
More informationIPOPI-AAIAT First Thai PID Patients National Meeting Novotel Ploenchit Hotel Bangkok, Thailand 29 September Report
IPOPI-AAIAT First Thai PID Patients National Meeting Novotel Ploenchit Hotel Bangkok, Thailand 29 September 2013 I. Introduction Report On Sunday 29 September 2013, the First Thai National PID Patients
More informationAN OPPORTUNITY FOR PRIMARY CARE
RARE DISEASES AN OPPORTUNITY FOR PRIMARY CARE Gerard Nguyen Primary Care, Cabinet Marcel Monny Lobe, Soisy sous Montmorency France Hopital Avicenne APHP Rett Syndrome Europe, AFSR, HUFERDIS (Hungary) RARE
More informationWORKING TOGETHER WITH PATIENT GROUPS
WORKING TOGETHER WITH PATIENT GROUPS September 2017 Developed by the EFPIA Patient Think Tank 1 FOREWORD Europe is facing significant healthcare challenges due to an ageing population and increased prevalence
More informationPCORI grants: dos and don ts from a reviewer s perspective. Margaret Olsen, PhD, MPH March 4, 2014
PCORI grants: dos and don ts from a reviewer s perspective Margaret Olsen, PhD, MPH March 4, 2014 Strategizing PCORI Grant Applications Different focus compared to NIH Essential to check PCORI website
More informationAnalysis Group, Inc. Health Economics, Outcomes Research, and Epidemiology Practice Areas
Analysis Group, Inc. Health Economics, Outcomes Research, and Epidemiology Practice Areas September 13, 2012 BOSTON CHICAGO DALLAS DENVER LOS ANGELES MENLO PARK MONTREAL NEW YORK SAN FRANCISCO WASHINGTON
More information2017 Oncology Insights
Cardinal Health Specialty Solutions 2017 Oncology Insights Views on Reimbursement, Access and Data from Specialty Physicians Nationwide A message from the President Joe DePinto On behalf of our team at
More informationPharmacovigilance: The patient s Perspective. Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA
Pharmacovigilance: The patient s Perspective Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA Scope of presentation Why is Pharmacovigilance important for patients?
More informationEuropean Patients Academy (EUPATI) Update
European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to
More informationRapid-Learning Healthcare Systems
Rapid-Learning Healthcare Systems in silico Research and Best Practice Adoption in Promoting Rapid Learning Sharon Levine MD July 11, 2012 NIH Training Institute for Dissemination and Implementation Rapid-Learning
More informationRules and Procedures for IMI Calls for proposals. IMI Webinar 17 July 2017
Rules and Procedures for IMI Calls for proposals IMI Webinar 17 July 2017 Outline 1. Introducing IMI 2. Participation rules 3. Funding rules 4. Intellectual property rules 5. From Call to grant award 6.
More informationAtaluren for treating nonsense mutation Duchenne muscular dystrophy (nmdmd)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Managed Access Agreement Ataluren for treating nonsense mutation Duchenne muscular dystrophy (nmdmd) Date of Agreement NHS England PTC Therapeutics International
More informationI write in response to your request for information in relation to neurology services in NHS Lothian.
Lothian NHS Board = Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG = Telephone: 0131 536 9000 www.nhslothian.scot.nhs.uk Date: 05/01/2016 Our Ref: 552 Enquiries to : Bryony Pillath Extension: 35676
More informationDevelopment Cycle-Time Metrics (We re Pretty Good at This)
Development Cycle-Time Metrics (We re Pretty Good at This) Study level Protocol Synopsis develop ed Protocol approved internally Planned first First Last Planned last First dose to first Last last visit
More informationLuke Timmerman. Timmerman Report, Moderator
Luke Timmerman Timmerman Report, Moderator An Imperative to Work Together Megatrends Forcing Horizontal R&D Foundations not just writing checks for basic research Internet makes it possible to mobilize
More informationClinical Research Networks
s Dr Natalie Pattison NIHR National Specialty Group Nursing Lead for Critical Care Trust lead for PPI in Research Senior Clinical Nursing Research Fellow The Royal Marsden NHS FT The UK research landscape
More informationMinistry of Health Patients as Partners Provincial Dialogue Report
Ministry of Health Patients as Partners 2017 Provincial Dialogue Report Contents Executive Summary 4 Introduction 6 Balanced Participation: Demographics and Representation at the Dialogue 8 Engagement
More informationImproving patient outcomes & health economics through connected health innovation
Improving patient outcomes & health economics through connected health innovation Session 103, February 21, 2017 Jeroen Tas, Chief Innovation & Strategy Officer, Philips Dr. Kevin Dellsperger, MD, PhD,
More informationSPECIFIED DISEASE CONDITIONS PROGRAM
SPECIFIED DISEASE CONDITIONS PROGRAM August 2017 www.hss.gov.nt.ca INTRODUCTION The Government of the Northwest Territories (GNWT) sponsors the Extended Health Benefits program to provide non-aboriginal
More informationRARE DISEASE DAY CONFERENCE 2018: Building on Research Excellence to Improve Patient Care Two-Day Interactive Conference
March 21-22, 2018 DELTA OTTAWA CITY CENTRE, 101 Lyon Street Ottawa, Ontario How this Conference Will Make a Difference (for Rare Diseases in Canada) Day 1 (AM) In May 2015, the Canadian Organization for
More informationBuilding Our Industrial Strategy Response to Government s Industrial Strategy Green Paper. from Alzheimer s Research UK
Building Our Industrial Strategy Response to Government s Industrial Strategy Green Paper Background to Alzheimer s Research UK from Alzheimer s Research UK April 2017 Alzheimer s Research UK is the leading
More informationThe Voice of Foreign Companies. Healthcare Policy Agenda. Bringing the Benefits of Innovative Practices to Denmark
The Voice of Foreign Companies Healthcare Policy Agenda Bringing the Benefits of Innovative Practices to Denmark November 24, 2008 Background The Healthcare Ambition We are convinced that Denmark has the
More informationCross-Border Enrollment of Rare Disease Patients
WHITE PAPER Cross-Border Enrollment of Rare Disease Patients Considerations for Planning & Conducting Global Rare Disease Clinical Trials Authors: AMY RAYMOND, PHD, PMP Clinical Scientist Scientific Affairs,
More informationFred Modell Diana Puente Vicki Modell
From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of Primary Immunodeficiencies Fred Modell Diana
More informationFOR-DMD FOR YOU! Newsletter 5 7 th April 2014 SITE ACTIVATION
Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Nov-13 Dec-13 Jan-14 Feb-14 Mar-14 Number of sites FOR-DMD FOR YOU! Newsletter 5 7 th April 14 SITE ACTIVATION Four more sites have
More informationMcKinley T34 Ambulatory syringe pump Used in the provision of adult palliative and end of life care
Health Guidance McKinley T34 Ambulatory syringe pump Used in the provision of adult palliative and end of life care Publication Code: HCR-0214-083 Publication date: 26 February 2014 Page 1 of 7 Health
More informationWHAT YOU SHOULD KNOW PATIENTS, PHYSICIANS AND CAREGIVERS
WHAT YOU SHOULD KNOW PATIENTS, PHYSICIANS AND CAREGIVERS Information and Checklists What You Should Know provides a summary of program requirements of the New Jersey Medicinal Marijuana Program (NJMMP).
More informationThe Patient Voice in Value:
The Patient Voice in Value: The National Health Council Patient-Centered Value Model Rubric March 2016 National Health Council 1730 M Street NW, Suite 500, Washington, DC 20036-4561 202-785-3910 The Patient
More informationAdministrators. Medical Directors. 61% The negative impact on our hospital-based program s. 44% We will need to consider the most appropriate or most
2016 This annual survey, which began in 2009, provides key insight into nationwide developments in the business of cancer care. To better capture information from its multidisciplinary membership, this
More informationAgenda for the next Government
Agenda for the next Government General election 2017 The Richmond Group of Charities We are the Richmond Group of Charities and we help people of all ages who have serious long term physical and mental
More informationSection IX Special Needs & Case Management
Section IX Special Needs & Case Management Special Needs and Case Management 181 Integrated Health Care Management (IHCM) The Integrated Health Care Management (IHCM) program is a population-based health
More informationMaking the most of patient registries
Making the most of patient registries Elizabeth Hernberg-Ståhl M.Sc. Stockholm October 15 Late Phase Solutions Europe AB Rare Disease Research Forum- Challenges and Solutions Stockholm KI, February 21,
More informationMONTEFIORE 1,491 beds 85,000 inpatient stays annually 7,000 births
MONTEFIORE Established in 1884 as a hospital for patients with chronic illnesses, Montefiore has grown and evolved to become a full service integrated healthcare delivery system serving a large and complex
More informationHealth Technology Assessment.
BROUGHT TO YOU BY Health Technology Assessment. Part 2: Health Economics and Outcome Research Created by Pfizer This learning module is intended for UK healthcare professionals only. Job bag: PP-GEP-GBR-1021
More informationAcceptance Speech. Writing Sample - Write. By K Turner
Acceptance Speech Thank you so much. Thank you to the committee for this recognition, thank you to the Texas Tech Administrators, and many thanks to my peer and friend who nominated me Jennifer Barnett.
More informationMasterclass NieuweZorg 3.0 De farmaceutische sector op Europees niveau. Author: Elizabeth Kuiper* Date: Maart 2016 * Presentation.
Masterclass NieuweZorg 3.0 De farmaceutische sector op Europees niveau Author: Elizabeth Kuiper* Date: Maart 2016 * Presentation www.efpia.eu About us Most businesses think that product is the most important
More informationSave up to $4,000 a year?!
Save up to $4,000 a year?! Indication and Usage HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is an immune globulin with a recombinant human hyaluronidase indicated
More informationSpread Pack Prototype Version 1
African Partnerships for Patient Safety Spread Pack Prototype Version 1 November 2011 Improvement Series The APPS Spread Pack is designed to assist partnership hospitals to stimulate patient safety improvements
More informationIMPROVED PATIENT OUTCOMES AND FINANCIAL PERFORMANCE THE VALUE OF INTEGRATED OUTSOURCED SERVICES SUPPORTING RARE DISEASE PHARMACEUTICAL COMPANIES.
IMPROVED PATIENT OUTCOMES AND FINANCIAL PERFORMANCE THE VALUE OF INTEGRATED OUTSOURCED SERVICES SUPPORTING RARE DISEASE PHARMACEUTICAL COMPANIES. By 2020, the global cost of orphan drugs is expected to
More informationKENYA Hereditary Angio Edema-Kenya
KENYA Hereditary Angio Edema-Kenya Patricia Karani HAEi Kenya Patient Represenative My Kenya Location - East Africa Capital city - Nairobi Population - 47 million people Currency - Kenya Shilling Language
More informationINNOVATIONS IN CARE MANAGEMENT. Michael Burcham, Narus Health
INNOVATIONS IN CARE MANAGEMENT Michael Burcham, Narus Health Innovations in Care Management Dr. Michael Burcham, CEO Narus Health Part 1 Care Management Trends & Headwinds Four Mega Trends Transforming
More informationYOUR TREATMENT NEEDS ARE OUR PRIORITY
YOUR TREATMENT NEEDS ARE OUR PRIORITY PTC CaresTM is your patient support program that s dedicated to helping you gain access to therapy. See inside to learn more Call 1-844-4PTC-CARES 8 AM - 8 PM EST
More informationCulture and Process Change as a Priority for Patient Engagement in Medicines Development
Policy: Analytical Report Culture and Process Change as a Priority for Patient Engagement in Medicines Development Therapeutic Innovation & Regulatory Science 2017, Vol. 51(1) 29-38 ª The Author(s) 2016
More informationWhat is the Jeffrey Modell Foundation? 2. What is Primary Immunodeficiency (PI)? What is the prevalence of PI? PI affects
1. What is the Jeffrey Modell Foundation? The Jeffrey Modell Foundation (JMF) is a 501(c)3 public charity established in 1987 by Vicki and Fred Modell in memory of their son, Jeffrey, who died at the age
More informationUNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
Gilead Sciences, Inc. GS-US-248-0123, Amendment 1, 19-JUN-2012 A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with
More informationMinutes of EMA Human Scientific Committees Working Party with Patients and Consumers Organisations (PCWP) meeting with all eligible organisations
31 January 2014 EMA/792279/2013 Patients and Healthcare Professionals Department Minutes of EMA Human Scientific Committees Working Party with Patients and Consumers Organisations (PCWP) meeting with all
More informationQUALITY IMPROVEMENT. Molina Healthcare has defined the following goals for the QI Program:
QUALITY IMPROVEMENT Molina Healthcare maintains an active Quality Improvement (QI) Program. The QI program provides structure and key processes to carry out our ongoing commitment to improvement of care
More informationIMPROVING HEALTH THROUGH
IMPROVING HEALTH THROUGH Our Community Update 2015/2016 INSTITUTE FOR BETTER HEALTH A MESSAGE FROM OUR LEADERSHIP This year, as we reflect on the growth of the Institute for Better Health, we are both
More informationBELGIAN EU PRESIDENCY CONFERENCE ON RHEUMATIC AND MUSCULOSKELETAL DISEASES (RMD)
BELGIAN EU PRESIDENCY CONFERENCE ON RHEUMATIC AND MUSCULOSKELETAL DISEASES (RMD) Brussels, 19 October 2010 Summary Report Background and Objectives of the conference The Conference on Rheumatic and Musculoskeletal
More informationIBM Watson Health Empowering Heroes. Transforming Health.
35 th Annual J.P. Morgan Healthcare Conference January 11, 2017 IBM Watson Health Empowering Heroes. Transforming Health. Deborah DiSanzo General Manager, IBM Watson Health Forward Looking Statements Certain
More informationSussex and East Surrey STP narrative
Sussex and East Surrey STP narrative What is the STP? The Sussex and East Surrey Sustainability and Transformation Partnership (STP) outlines how the NHS and social care will work together to improve and
More informationPopulation and Community Health Nursing, 6e (Clark) Chapter 7 Health System Influences on Population Health
Instant download and all chapters Test Bank Population and Community Health Nursing 6th Edition Mary Jo Clark https://testbanklab.com/download/test-bank-population-community-health-nursing-6thedition-mary-jo-clark/
More informationWhat is EUPATI? The EUPATI project receives support from the European Union (IMI JU) and EFPIA companies
What is EUPATI? The EUPATI project receives support from the European Union (IMI JU) and EFPIA companies EUPATI: Summary EU Patients Academy approved for funding Innovative and ambitious project Patient-led
More informationDisclosures. Platforms for Performance: Clinical Dashboards to Improve Quality and Safety. Learning Objectives
Platforms for Performance: Clinical Dashboards to Improve Quality and Safety Disclosures The program chair and presenters for this continuing pharmacy education activity report no relevant financial relationships.
More informationRegulatory Updates Health Sciences Authority Singapore
Regulatory Updates Health Sciences Authority Singapore Wong Woei Jiuang Director, Medical Devices Branch, Health Sciences Authority, Singapore Background Scope Pre-market Consultation (PMC) Scheme Medical
More informationDuke-Margolis Center: Overview And High Priority Projects in Biomedical Innovation and Payment
Duke-Margolis Center: Overview And High Priority Projects in Biomedical Innovation and Payment Gregory Daniel, PhD, MPH Deputy Director, Duke-Margolis Center for Health Policy Clinical Professor, Fuqua
More informationPatient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force
5 May 2017 EMA/180341/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force EMA Initiative 1.
More informationWoking & Sam Beare Hospices
Woking & Sam Beare Hospices Introduction Woking Hospice was set up 20 years ago. From that early beginning, it has developed to become a local centre of excellence, as is the case with all Hospices in
More informationCoastal Medical, Inc.
A Culture of Collaboration The Organization Physician-owned group Currently 19 offices across the state of Rhode Island and growing 85 physicians, 101 care providers The Challenge Implement a single, unified
More informationCONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION
CONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION November 2016 ABOUT CORD The Canadian Organization for Rare Disorders (CORD) provides a strong common voice to advocate for health policy and a healthcare
More informationStrategic Plan
The Irish Hospice Foundation Strategic Plan 2016-2019 The Irish Hospice Foundation 1 Strategic Plan 2016-2019 Our Vision No-one will face death or bereavement without the care and support they need. Our
More informationGuidance on End of Life Care-Updated July 2014
Guidance on End of Life Care-Updated July 2014 INTRODUCTION Definition of End of Life Care: End of Life care helps all those with advanced, progressive, incurable illness to live as well as possible until
More informationRe: Docket No. FDA-2017-N-0455: Enhancing Patient Engagement Efforts Across FDA; Establishment of a Public Docket; Request for Comments.
June 12, 2017 Division of Dockets Management (HFA-305) U.S. Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. FDA-2017-N-0455: Enhancing Patient Engagement Efforts
More informationInformal note on the draft outline of the report of WHO on progress achieved in realizing the commitments made in the UN Political Declaration on NCDs
Informal note on the draft outline of the report of WHO on progress achieved in realizing the commitments made in the UN Political Declaration on NCDs (NOT AN OFFICIAL DOCUMENT OR FORMAL RECORD 1 ) Geneva,
More informationAn introduction to AXREM the Trade Association of Healthcare Technology providers for Imaging, Radiotherapy and care.
ASSOCIATION OF HEALTHCARE TECHNOLOGY PROVIDERS FOR IMAGING, RADIOLOGY & CARE An introduction to AXREM the Trade Association of Healthcare Technology providers for Imaging, Radiotherapy and care. Welcome
More informationJoy At Work - BellinHealth and HealthPartners
Joy At Work - BellinHealth and HealthPartners Restoring Joy in Practice through Team Based Care IHI December 2016 James Jerzak M.D. Kathy Kerscher Bellin Health Green Bay, Wisconsin 1 Agenda Crisis Emerging
More informationRt hon Jeremy Hunt MP Secretary of State for Health and Social Care. Letter by to Dear Jeremy
Health and Social Care Committee House of Commons London SW1A 0AA Tel: 020 7219 6182 Fax 020 7219 5171 Email: hsccom@parliament.uk Website: www.parliament.uk/hsccom Twitter: @CommonsHealth From Dr Sarah
More informationpresents OHIO biomedical and pharma career fair April 15 2pm 6pm Columbus, Ohio Exhibitor Booklet
presents OHIO biomedical and pharma career fair 2013 April 15 2pm 6pm Columbus, Ohio Exhibitor Booklet Exhibitors Aerotek Scientific Alliance Scientific Amylin Ohio Aptalis Pharmatech Cardinal Health Diagnostic
More informationPATIENT CENTERED. Medical Home. Attestation. Facility Compliance
2 0 1 7 Attestation PATIENT CENTERED Medical Home of Facility Compliance State of Wyoming, Department of Health, Division of Healthcare Financing Check the Patient Centered Medical Home (PCMH) Programs
More informationHip fracture Quality Improvement Programme. Update on progress one year on
Hip fracture Quality Improvement Programme Update on progress one year on Mike Reed on behalf HIPQIP Steering Group March 2011 Introduction Hip fracture is a common condition in a frail and elderly group.
More informationCare Programme Approach (CPA)
Care Programme Approach (CPA) The Care Programme Approach (CPA) is a package of care that may be used to plan your mental health care. This factsheet explains what CPA is, when you should get and when
More informationEnsuring Quality Health Care in Health Reform
Ensuring Quality Health Care in Health Reform What Is Quality Health Care? Put simply, it s the right care, at the right time, for the right reason. It s the care we all deserve but, sadly, it s not the
More informationWebinar #5 Meaningful Use: Looking Ahead to Stage 2 and CPS 12
New York State-Health Centered Controlled Network (NYS HCCN) Webinar #5 Meaningful Use: Looking Ahead to Stage 2 and CPS 12 December 10, 2013 Ekem Merchant-Bleiberg, Director of Implementation Services
More informationNational Guidelines for a Comprehensive Service System to Support Family Caregivers of Adults with Mental Health Problems and Illnesses SUMMARY
National Guidelines for a Comprehensive Service System to Support Family Caregivers of Adults with Mental Health Problems and Illnesses SUMMARY Prepared by Penny MacCourt, MSW, PhD and the Family Caregivers
More information340B Drug Program Summary
Summary Congress created section 340B of the Public Health Service Act in 1992 to allow eligible health care providers known as Covered Entities to stretch scarce Federal resources, reaching more patients
More informationAffirmation Statement of Vaccine Safety
Affirmation Statement of Vaccine Safety This Affirmation Statement is made by and between (Patient s Name, Hereinafter You ), and (name of healthcare practitioner, Hereinafter I ), and made effective as
More informationDissemination and Communication Strategy Plan
Dissemination and Communication Strategy Plan Submission: 30.10.2017 This Dissemination Plan was funded by the European Union s Health Programme (2014-2020). The content of this Dissemination Plan represents
More informationIntroduction to QI and HIT. Objectives. Health Care. Unit 1a: Health Care Quality and HIT
Introduction to QI and HIT Unit 1a: Health Care Quality and HIT This material was developed by Johns Hopkins University, funded by the Department of Health and Human Services, Office of the National Coordinator
More informationForward-Looking Statements
Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks,
More informationHIMSS Davies Enterprise Application --- COVER PAGE ---
HIMSS Davies Enterprise Application --- COVER PAGE --- Applicant Organization: Hawai i Pacific Health Organization s Address: 55 Merchant Street, 27 th Floor, Honolulu, Hawai i 96813 Submitter s Name:
More information